Neural regeneration peptides and methods for their use in treatment of brain damage

• US 7,563,862 B2
• Filed: 10/29/2004
• Issued: 07/21/2009
• Est. Priority Date: 08/24/2001
• Status: Active Grant

• Current Assignee: Curonz Holdings Company Limited
• Original Assignee: Neuren Pharmaceuticals Limited
• Inventors: Hughes, Paul Edmund, Gorba, Thorsten, Sieg, Frank
• Primary Examiner(s): Saoud; Christine J
• Assistant Examiner(s): WANG, CHANG YU
• Application Number:
  US10/976,699
• Publication Number:
  US 20050131212A1
• Time in Patent Office: 1,726 Days
• Field of Search: None
• US Class Current: 530/300
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: A61K 38/17 from animals; from humans enzyme inhibitors A61K38/005
• CPC Class Codes: A61K 48/00 Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
• CPC Class Codes: C07H 21/04 with deoxyribosyl as saccharide radical
• CPC Class Codes: C07K 14/705 Receptors; Cell surface antigens; Cell surface determinants tumour specific antigens C07K14/4748
• CPC Class Codes: C12Q 1/68 involving nucleic acids

Abstract

The invention discloses a family of peptides termed NRP compounds or NRPs that can promote neuronal migration, neurite outgrowth, neuronal proliferation, neural differentiation and/or neuronal survival, and provides compositions and methods for the use of NRPs in the treatment of brain injury and neurodegenerative disease. NRP compounds can induce neurons and neuroblasts to proliferate and migrate into areas of damage caused by acute brain injury or chronic neurodegenerative disease, such as exposure to toxins, stroke, trauma, nervous system infections, demyelinating diseases, dementias, and metabolic disorders. NRP compounds may be administered directly to a subject or to a subject'"'"'s cells by a variety of means including orally, intraperitoneally, intravascularly, and directly into the nervous system of a patient. NRP compounds can be formulated into pharmaceutically acceptable dose forms for therapeutic use. Methods for detecting neural regeneration, neural proliferation, neural differentiation, neurite outgrowth and neural survival can be used to develop other neurally active agents.

Claims

1. An isolated peptide consisting of a sequence selected from the group consisting of SEQ ID NO:

29, SEQ ID NO;

30, SEQ ID NQ;

33, SEQ ID NO;

34, SEQ ID NO;

43, SEQ ID NO;

44, SEQ ID NO;

45, and SEQ ID NO;

46.

2. The isolated peptide of claim 1, consisting of the sequence of SEQ ID NO:

29.

3. The isolated peptide of claim 1, consisting of the sequence of SEQ ID NO:

30.

4. The isolated peptide of claim 1, consisting of the sequence of SEQ ID NO:

33.

5. The isolated peptide of claim 1, consisting of the sequence of SEQ ID NO:

34.

6. The isolated peptide of claim 1, consisting of the sequence of SEQ ID NO:

43.

7. The isolated peptide of claim 1, consisting of the sequence of SEQ ID NQ:

44.

8. The isolated peptide of claim 1, consisting of the sequence of SEQ ID NO:

45.

9. The isolated peptide of claim 1, consisting of the sequence of SEQ ID NO:

46.

10. A method for promoting neural cell proliferation in a mammal suffering from a neurodegenerative disorder due to hypoxia/ischemia, comprising administering to said mammal a pharmaceutically effective amount of a peptide having the sequence of SEQ ID NO:

34.

11. The method of claim 10 where the neural cell is a neuron.

12. The method of claim 10, wherein said hypoxia/ischemia is due to one or more conditions selected from the group consisting of stroke, decreased perfusion caused by cardiac insufficiency/coronary bypass surgery, atherosclerotic thrombosis, embolism, hypertensive haemorrhage, ruptured aneurysm, vascular malformation, transient ischemic attack, intracranial haemorrhage, spontaneous subarachnoid haemorrhage, traumatic brain injury, traumatic intracerebral haemorrhage, cerebral contusion, basal skull fracture and hypertensive encephalopathy.

13. The method of claim 10, wherein said peptide is administered via a route selected from the group consisting of intravenous, intracerebral, lateral cerebroventricular, subcutaneous, intracisternal and parenteral.

14. A method for promoting neural cell migration in a mammal suffering from a neurodegenerative disorder due to hypoxia/ischemia, comprising administering to said mammal a pharmaceutically effective amount of a peptide having a sequence selected from the group consisting of SEQ ID NO:

29, SEQ ID NO;

30 and SEQ ID NO;

34.

15. The method of claim 14 where the neural cell is a neuron.

16. The method of claim 14, wherein said hypoxia/ischemia is due to one or more conditions selected from the group consisting of stroke, decreased perfusion caused by cardiac insufficiency/coronary bypass surgery, atherosclerotic thrombosis, embolism, hypertensive haemorrhage, ruptured aneurysm, vascular malformation, transient ischemic attack, intracranial haemorrhage, spontaneous subarachnoid haemorrhage, traumatic brain injury, traumatic intracerebral haemorrhage, cerebral contusion, basal skull fracture and hypertensive encephalopathy.

17. The method of claim 14, wherein said peptide is administered via a route selected from the group consisting of intravenous, intracerebral, lateral cerebroventricular, subcutaneous, intracisternal and parenteral.

18. A method for promoting neural cell survival in a mammal suffering from a neurodegenerative disorder due to hypoxia/ischemia, comprising administering to said mammal a pharmaceutically effective amount of a peptide having a sequence selected from the group consisting of SEQ ID NO:

30, SEQ ID NO;

34 and SEQ ID NO;

43.

19. The method of claim 18 where the neural cell is a neuron.

20. The method of claim 18, wherein said hypoxia/ischemia is due to one or more conditions selected from the group consisting of stroke, decreased perfusion caused by cardiac insufficiency/coronary bypass surgery, atherosclerotic thrombosis, embolism, hypertensive haemorrhage, ruptured aneurysm, vascular malformation, transient ischemic attack, intracranial haemorrhage, spontaneous subarachnoid haemorrhage, traumatic brain injury, traumatic intracerebral haemorrhage, cerebral contusion, basal skull fracture and hypertensive encephalopathy.

21. The method of claim 18, wherein said peptide is administered via a route selected from the group consisting of intravenous, intracerebral, lateral cerebroventricular, subcutaneous, intracisternal and parenteral.

22. A method for promoting neural cell differentiation in a mammal suffering from a neurodegenerative disorder due to hypoxia/ischemia, comprising administering to said mammal a pharmaceutically effective amount of a peptide having the sequence of SEQ ID NO:

33.

23. The method of claim 22 where the neural cell is a neuron.

24. The method of claim 22, wherein said hypoxia/ischemia is due to one or more conditions selected from the group consisting of stroke, decreased perfusion caused by cardiac insufficiency/coronary bypass surgery, atherosclerotic thrombosis, embolism, hypertensive haemorrhage, ruptured aneurysm, vascular malformation, transient ischemic attack, intracranial haemorrhage, spontaneous subarachnoid haemorrhage, traumatic brain injury, traumatic intracerebral haemorrhage, cerebral contusion, basal skull fracture and hypertensive encephalopathy.

25. The method of claim 22, wherein said peptide is administered via a route selected from the group consisting of intravenous, intracerebral, lateral cerebroventricular, subcutaneous, intracisternal and parenteral.

26. A method for promoting neurite growth in a mammal suffering from a neurodegenerative disorder due to hypoxia/ischemia, comprising administering to said mammal a pharmaceutically effective amount of a peptide having a sequence selected from the group consisting of SEQ ID NO:

30, SEQ ID NO;

34, SEQ ID NO;

44, SEQ ID NO;

45 and SEQ ID NO;

46.

27. The method of claim 26, wherein said hypoxia/ischemia is due to one or more conditions selected from the group consisting of stroke, decreased perfusion caused by cardiac insufficiency/coronary bypass surgery, atherosclerotic thrombosis, embolism, hypertensive haemorrhage, ruptured aneurysm, vascular malformation, transient ischemic attack, intracranial haemorrhage, spontaneous subarachnoid haemorrhage, traumatic brain injury, traumatic intracerebral haemorrhage, cerebral contusion, basal skull fracture and hypertensive encephalopathy.

28. The method of claim 26, wherein said peptide is administered via a route selected from the group consisting of intravenous, intracerebral, lateral cerebroventricular, subcutaneous, intracisternal and parenteral.